MUC1 and melanoma: Similar to the findings in the preventive mouse model, these results also showed that five immunizations with the recombinant MUC1-MBP vaccine more significantly inhibited B16-MUC1 melanoma growth than eight immunizations in the therapeutic mouse model, and that this greater inhibition was accompanied by a higher IgG2c/IgG1 ratio, more MUC1-specific lymphocyte proliferation, higher IFN-γ secretion by lymphocytes, and higher CTL cytotoxicity (Figure 6B–H).